- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
102
has also focused on the development of new, ‘‘unconventional’’ perimetric techniques for diagnosing and monitoring the earliest glaucomatous changes. Although a number of techniques are now available (short-wavelength automated perimetry, SWAP, or blue-on-yellow perimetry; fre- quency-doubling technology perimetry, FDT; motion-automated perimetry, MAP; high-pass resolution perimetry, HPRP), the most largely used in clinical settings are SWAP and FDT. The aim of this article is to review the rationale, the most relevant clinical data available in literature, and the tasks required to improve the clinical usefulness of these two instruments.
Retinal ganglion cells: anatomy and function
In the human visual system, RGCs project to relay cells in the layers of the dorsal lateral geniculate nucleus (LGN), which project to the primary visual cortex. All retinal and optic nerve head (ONH) diseases determine the death of the first axon of this pathway (in glaucoma through apoptosis). The primary damage causes a secondary atrophy of the LGN (Weinreb et al., 1994) and, ultimately, a loss of information projected to the visual cortex (Yucel et al., 2003; Gupta and Yucel, 2007). A full comprehension of the anatomy and the physiology of RGC is therefore required to understand the mechanisms by which the disease may induce changes in the visual function.
Recent electrophysiology studies on primates provided evidence that the retina is endowed with three primary pathways: parvocellular (P-cells), magnocellular (M-cells), and koniocellular (K-cells) (Kaplan, 2004; Callaway, 2005). This subdivision into different pathways is maintained through the LGN (Kaplan, 2004; Callaway, 2005), while the projections to the cortex are both anatomically and functionally much less segregated (Dobkins and Albright, 2004; Kaplan, 2004). In addition to these pathways, a number of other ganglion cell types connect to the LGN (Polyak, 1941) whose functional properties and postsynaptic targets still remain unidentified (Callaway, 2005).
Table 1 summarizes the main features of the subgroups of RGCs. Although this classification is
almost universally adopted, it must be remembered that the fiber diameter is influenced not only by the ganglion cell type but also by eccentricity: fibers within the central retina are thinner than those projecting from the peripheral retina. As a consequence, larger diameter fibers are not exclusively magnocellular: some eccentric parvocellular RGC axons may be even larger than more central magnocellular ones.
P-cells represent nearly 80% of RGC. They are generally small in size and located in the whole retina, although they have a very high concentration in the macular region; their receptive fields are much smaller than M- and K-pathways and they have substantial overlapping. Conducting velocity of P-cells is slower than K- and M-cells. P-cells are responsible for detecting, encoding, and transmitting information about colored, high-contrast, low temporal frequency (i.e., static) stimuli, although M- and K-cells can detect the same stimuli, albeit with a lower sensitivity (Solomon et al., 2002). An example of a selective stimulation of P-neurons is represented by the projection to the retina of the smallest letters of a standard Snellen chart used to test visual acuity.
P-cells can be classified as central and peripheral. Central P-cells are sensitive to color vision, and they can be subdivided in red-ON, red-OFF, green-ON, green-OFF, and, probably, blue-OFF. Peripheral P-cells comprise two groups (luminance-ON and -OFF) and they are sensitive to luminance (Callaway, 2005). P-cells can be also classified as type I and II on the basis of their receptive organization (type I has a centre–surround organization; type II is less diffuse and has coextensive ON and OFF regions) (Callaway, 2005).
Within the same retina region (see above), M-cells are larger than the other RGCs; they represent about 10% of all RGCs and they are endowed with low redundancy (Sample et al., 2000a, b). M-cells are located in the peripheral retina and they have large receptive fields with very limited overlapping. Within RGCs, M-cells have the fastest conduction of the stimulus. They are sensitive to low-contrast, high-temporal frequency (i.e., motion) stimuli (Solomon et al., 2005); for example, a black car rapidly passing by a driver’s side window at night would selectively stimulate M-pathway neurons.
|
|
|
103 |
Table 1. Subtypes and features of RGCs |
|
|
|
|
|
|
|
|
Cell pathway |
|
|
|
|
|
|
|
K |
M |
P |
|
|
|
|
Percentage |
9% |
10% |
80% |
Receive input from |
Mainly bistratified (blue-ON) |
Parasol retinal ganglion cells |
Midget retinal ganglion |
|
retinal ganglion cells |
|
cells |
Location in LGN |
Within and between principal |
Most ventral (layers 1 and 2) |
Most dorsal (layers 3 to 6) |
|
layers (interlaminar) |
|
|
Sensitive to |
Shorter wavelengths, moderate |
Higher temporal frequencies |
Higher spatial frequencies |
|
spatial resolution |
(movement) |
(detail), colors, luminance |
Retinal location |
Diffuse |
Increasing with eccentricity |
Decreasing with |
|
|
|
eccentricity |
Redundancy |
Low |
Low |
High |
Conducting velocity |
Intermediate |
Fast |
Slow |
Receptive field size |
Very large |
Large |
Small |
Segregation |
High |
High |
Low |
Isolation |
15 dB |
Unknown |
Unknown |
|
|
|
|
It has been speculated that a portion of the M-cell population, the My cells, serves as the primary basis for the frequency-doubling phenomenon (Maddess and Henry, 1992). The response of this subgroup of cells is supposed to be independent by the wavelength of the stimulus, a feature that differentiates them from all the other RGCs, which show a biphasic response at the variation of stimulus wavelength (Solomon et al., 2005).
The third subgroup of RGCs is represented by koniocells. Literally, ‘‘koniocells’’ means ‘‘cells as small as dust.’’ This term was used because, due to their small size, it was very difficult to detect them in the context of the peripheral retina, where they are located. Studies on animal models recently improved our knowledge of K-cells: They represent a small subgroup (about 9%) of RGCs of small size (though they are larger than P-cells) and little redundancy (DeMonasterio, 1979); they are sparse in location and their receptive field is very large with no surrounds (Callaway, 2005); they are heterogeneous both in structure and function, and different subtypes have been identified. An important reduction of the subtype of koniocells expressing CaMKII-a has been shown in a model of glaucoma in monkeys compared to controls (10,45678770 neurons in glaucoma vs. 73,3037 15,776 in controls) (Yucel et al., 2003).
The main function of K-cells is to process blue– yellow color vision (Dacey and Lee, 1994).
Information on the blue–yellow axis is captured by blue-ON receptors, projected by koniocells within and between the principal layers of LGN; the stimulus is conducted with intermediate velocity. K-cells also respond to stimuli with moderate spatial resolution (i.e., moderate contrast).
Is glaucoma damage selective for any subgroup of RGCs?
Over the last decades, a strong debate arose on the RGC-selectivity of glaucoma damage. Scientists dealing with unconventional perimetries supported the hypothesis that glaucoma damage was selective for the subgroups of RGCs isolated by those visual field techniques (Maddess and Henry, 1992). Yet the hypothesis of the selectivity of glaucoma damage was brilliantly confuted by Harwerth et al. (1999). In their experimental study in primate animal models of glaucoma, evaluated with psychophysics, electrophysiology, anatomy, and histochemistry, the authors showed that glaucomatous atrophy causes a nonselective reduction of metabolism of magnocellular and parvocellular neurons in the afferent visual pathway. Such findings were confirmed by Yucel et al. (2003), who showed the absence of selective cell loss within the LGN in experimental glaucoma models. Although few scientists still argue that not all glaucoma cases behave in the same way (with
104
individuals showing damage first to K-cells, others to M-cells, and others to P-cells), after these findings the nonselectivity of glaucoma damage seems demonstrated: as M-, K-, and P-cells are equally affected by the disease, a hypothetical 10,000-fiber loss would determine the loss of 8000 P-cells, 1000 M-cells, 900 K-cells, and 100 non-P, -M, -K-cells.
As a corollary to the assumption of nonselectivity of glaucoma damage, one would expect that perimetric techniques which use stimuli that are detected by all ganglion subsets (such as SAP) would have the same diagnostic power than those which selectively test a single pathway (such as SWAP and FDT), a fact that has been refuted by many clinical studies (see below). How can this discrepancy be possible? In order to answer this question, some functional aspects of the visual system must be considered in more detail: they are segregation, isolation, receptive field organization, and redundancy.
Segregation
We previously stated that visual pathways have a well-defined anatomical segregation up to the LGN. Functional segregation is present as well, but probably only for M- and K-cells. In the presence of damage to these cells, the visual system has a reduced ability to use other subsets of RGCs to compensate their information (Kaplan, 2004; Callaway, 2005). On the opposite end, both M- and K-cells are also sensitive to the colored, highcontrast, static stimuli, and they can therefore substitute P-cells on the transmission of information to the visual cortex in the case of damage to the P-pathway.
This only partial functional segregation may explain by itself how, though all subtypes of RGCs are damaged in glaucoma, tests that favor detection of a stimulus by one visual pathway (for example, FDT for M-cells, and SWAP for K-cells) reduce the ability of the visual system to use other pathways to compensate for the damaged RGC type (Kaplan, 2004; Callaway, 2005). When visual function is tested by SAP, such a compensation would occur.
Isolation
In a visual pathway, isolation defines the amount of sensitivity, which has to be lost before another cell type could assist in responding to the stimulus.
Up to now, the amount of isolation is unknown for retinal pathways, except for K-cells stimulated by blue-on-yellow targets, which provide approximately 15 dB of isolation. This means that the blue–yellow ganglion cell system would have to lose 15 dB of sensitivity before another cell type could assist in responding to the SWAP stimulus (Sample et al., 1996). Together with segregation, isolation reduces the likelihood of other visual pathways to compensate for initial damage (at least for K-cells), thus confirming the potential diagnostic superiority of techniques which selectively test one visual pathway.
Receptive field structure and redundancy
The receptive field is the area of the visual space where presentation or withdrawal of light causes changes in the action potential firing of the visual responsive unit (Hartline, 1940; Polyak, 1941; Kuffler, 1953; Hubel and Wiesel, 1959; Solomon et al., 2002). Visual responsive units therefore represent the functional units of the peripheral visual system; each unit is composed of a variable number of retinal receptors, intraretinal cells, and a single RGC, which brings information to the brain. Intraretinal cells downand up-regulate the excitability of the whole functional unit and of the neighboring ones, and they create a variable overlapping between contiguous receptive fields; they comprise bipolar cells (which connect receptors to RGCs), horizontal cells (which interconnect receptors inside and outside the receptive field), and amacrine cells (which create a network of connections between contiguous RGCs).
Receptive fields are circular and their dimensions are proportional to the number of retinal receptors, which are connected to a single RGC. The size of the receptive fields increases with eccentricity. In the fovea, the ratio between receptors and RGCs is about 16:1, while in the peripheral retina, nearly 1500 receptors project to a single RGC. As a consequence, central vision has
